drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Chimeric IgG1 anti–TNF-α monoclonal antibody that neutralizes soluble and transmembrane TNF-α, suppressing TNF-driven signaling, cytokine release, leukocyte recruitment, and inducing apoptosis of activated immune cells.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds and neutralizes soluble and transmembrane TNF-α, blocking TNF receptor signaling (e.g., NF-κB activation), thereby reducing pro-inflammatory cytokine release and leukocyte recruitment, and can induce apoptosis of activated TNF-expressing immune cells.
drug_name
Infliximab
nct_id_drug_ref
NCT06614387